This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics

Prices will rise in...

  • 00
  • 00
  • 00
  • 00
12 - 14 Nov 2024
Hamburg Congress CentreHamburg, Germany

Karina Thorn, PhD
Corporate VP and Head of Research, Global Nucleic Acid Therapies (GNAT) at Novo Nordisk


Karina Thorn is a highly accomplished leader and innovator in the field of biotechnology, currently serving as Corporate VP and Head of Research, Global Nucleic Acid Therapies (GNAT). Her previous position was Corporate Vice President of RNA and Gene Therapies. With a Ph.D. in Biochemistry from the Faculty of Pharmaceutical Sciences at the University of Copenhagen, Denmark, Karina possesses a strong academic foundation and a deep understanding of the intricacies of the field.

After completing her doctoral studies, Karina gained valuable experience working in Boston, United States, before joining Novo Nordisk research organization in 2014. Since then, she has played a pivotal role in driving research projects focused on rare diseases as well as more prevalent serious chronic diseases.

In addition to her scientific contributions, Karina has also excelled in management roles within Novo Nordisk. She has been leading departments and projects alongside being instrumental in establishing a diverse network of external partnerships for Novo Nordisk. Her passion for unlocking therapeutic innovation through emerging technologies has been a driving force behind global collaborations united by science.

Agenda Sessions

  • Intracellular Therapies and Oligonucleotide Applications